SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following a strong earnings beat and robust Q1 guidance driven by surging data center demand, sparking intense community debate despite the impressive financials. While many anticipate a significant rally, others caution of a 'sell the news' scenario, citing ongoing skepticism regarding AI valuation and perceived market manipulation impacting options traders.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is experiencing a significant sell-off after providing softer-than-expected Q1 guidance, despite beating Q4 revenue and earnings estimates, fueling intense investor debate. Many express frustration over the prolonged stock decline and executive compensation, while others view the sharp drop as an oversold opportunity, highlighting the company's profitability and strong customer retention in the competitive ad tech sector.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending after receiving FDA Breakthrough Therapy Designation for its Friedreich's ataxia treatment, igniting bullish comparisons to multi-billion dollar acquisitions, though a recently priced $100 million public offering is fueling debate among investors over dilution versus strategic funding for commercialization.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG CRYPTO) is trending as its community celebrates a one-year anniversary and the recent launch of its "incinerator," which executes continuous buybacks and burns to tighten supply. Holders are bullish on its passive income mechanism, which automatically distributes Solana rewards.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

An increase in ImmunityBio's (IBRX) shares outstanding, stemming from debt conversion and founder Patrick Soon-Shiong's reaffirmed majority ownership, is driving fervent community debate over the stock's true free float and massive short interest; this occurs amidst recent global regulatory approvals and significant revenue growth, leaving bulls anticipating a short squeeze while skeptics raise dilution concerns.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals (AUPH) is actively discussed ahead of its Q4 earnings report, with investor sentiment focused on overdue updates for the AUR200 Phase 2 pipeline and continued Lupkynis sales performance. Community hopes for a significant catalyst, potentially a buyout, are tempered by past management communication issues, despite notable institutional accumulation.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to its recent earnings report, emphasizing its critical role in advanced GaN and SiC power solutions for next-gen AI data centers and EVs, especially within NVIDIA's ecosystem. The community is keenly watching for concrete, revenue-generating partnerships that could validate its long-term potential, despite current revenue declines prompting market debate.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as its earnings approach, driven by heightened speculation around new Matrix-M licensing deals in oncology and for C. diff, fueling community hopes for a short squeeze and a resolution to long-standing frustrations over strategic execution.

Direxion Shares ETF Trust - Direxion Daily South Korea Bull 3X Shares

Direxion Daily South Korea Bull 3X Shares

KORU is skyrocketing on an extraordinary rally in South Korean equities, propelled by semiconductor powerhouses Samsung and SK Hynix amid booming High Bandwidth Memory chip demand for AI processing. The community is actively discussing its immense gains, anticipating further momentum from the country's recent short-selling ban and ongoing market reforms.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is rallying significantly after a strong Q4 earnings report highlighted robust growth in USDC circulation and adjusted EBITDA, propelling community discussion about its role as a foundational stablecoin platform. Bulls anticipate a substantial short squeeze and triple-digit price targets, while a vocal contingent of bears warns of an overextended rally ripe for profit-taking amidst ongoing debates about its valuation and crypto market correlation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been assigned a consensus rating of "Buy" from the eleven analysts that are presently covering the firm, MarketBeat.com reports...

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge

Key PointsChief Medical Officer Harold Bernstein exercised 15,000 shares, which were sold immediately for a total transaction value of approximately $690,300 on Feb. 2, 2026...

Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit

Maze Therapeutics (NASDAQ:MAZE) is advancing a genetics-driven approach to drug development, using human genetic analyses to identify gene variants linked to disease and then applying those insights...

Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 15,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of...

Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High - Should You Buy?

Maze Therapeutics (NASDAQ:MAZE) Hits New 12-Month High - Time to Buy...

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Thursday, January 29th. The stock was sold at an...

Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE

Strs Ohio cut its position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 61.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and...

Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock

Key PointsAmy Bachrodt exercised 5,000 shares and immediately sold them for approximately $227,612 on Jan. 22, 2026...

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an...

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Current Price	$47.23
Prev Close	$45.30
Open	$45.59
Dividend Yield	N/A
50-Day Moving Average	$43.00
Beta	1.01
Avg. Volume	396,215.50
PE Ratio	-20.09

52-Week High	$49.25
52-Week Low	$6.71
Market Capitalization	$2.18B
EPS (Annual)	$0.0778
Price to Book	5.74
Revenue Per Employee	$1.34M

MAZE
Maze Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAZE News

MAZEMaze Therapeutics Inc.